Skip to main content
Clinical Trials/NL-OMON32545
NL-OMON32545
Recruiting
N/A

The added value of MRI for detection of prostate cancer: validation with MR guided biopsies, fusion of MRI and transrectal ultrasound guided biopsies and TRUS guided biopsies. - Detection of prostate cancer: MRGB, TRUSGB and MRUSFGB

niversitair Medisch Centrum Sint Radboud0 sites60 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
prostate cancer
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
60
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • PSA\>\=4\.0 ng/ml
  • One or more previous negative TRUS guided prostate biopsies

Exclusion Criteria

  • Patients with known contradictions to MRI
  • Patients with known contra\-indications to Gadolinium based contrast agents.
  • Patients with previous radiotherapy, hormonal therapy or local treatment of the prostate.
  • Patients with histological prove of prostate cancer

Outcomes

Primary Outcomes

Not specified

Similar Trials